The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.
Complete resolution of nonalcoholic fatty liver disease (NAFLD) is highly likely to occur following sustained weight loss in obese patients who have undergone bariatric surgery, although there are still some who may develop new or worsened features of NAFLD, a study has shown.
Microbial therapies, such as prebiotics and probiotics, show potential in patients with nonalcoholic fatty liver disease, yielding reductions in body mass index, hepatic enzymes, serum cholesterol and triglycerides, a study has shown.
Coeliac disease patients have a threefold risk of nonalcoholic fatty liver disease (NAFLD) despite adherence to a gluten-free diet, a study has found. This risk is especially higher in the lean population.
Supplementation with omega-3 long-chain polyunsaturated fatty acids appears beneficial to patients with nonalcoholic fatty liver disease (NAFLD), producing significant improvements in liver fat content, steatosis score and several cardiometabolic risk factors, according to a systematic review and meta-analysis.
In Asian patients with nonalcoholic fatty liver disease, more severe liver disease is associated with factors such as older age, obesity, diabetes, dyslipidaemia, higher alanine transaminase and aspartate transaminase levels, and lower platelet count, according to a team of investigators.
Multiparametric magnetic resonance imaging (MRI) accurately identifies patients with nonalcoholic fatty liver disease (NAFLD), stratifying between nonalcoholic steatohepatitis and simple steatosis as well as between low and high risk of progressive liver disease, according to a study. However, the approach appears to be inferior for staging of fibrosis.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.